Renovaro Inc. Restates Financials Due to Equity Transaction Review

TL;DR

Renovaro's financials are unreliable, expect restatements.

AI Summary

Renovaro Inc. announced on August 14, 2024, that it will not rely on previously issued financial statements for the fiscal year ended June 30, 2024, and interim periods thereafter. This decision stems from an ongoing review of its accounting for certain non-cash equity transactions, which may impact previously reported results.

Why It Matters

Investors should be aware that past financial reports may be inaccurate, requiring a re-evaluation of the company's financial health and performance.

Risk Assessment

Risk Level: medium — The company is withdrawing previously issued financial statements, indicating potential accounting issues that could affect investor confidence and valuation.

Key Players & Entities

• Renovaro Inc. (company) — Registrant
• August 14, 2024 (date) — Date of earliest event reported
• June 30, 2024 (date) — Fiscal year end for affected financial statements

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar

Filing Documents

• e5891_8-k.htm (8-K) — 29KB
• 0001731122-24-001283.txt ( ) — 199KB
• renb-20240814.xsd (EX-101.SCH) — 3KB
• renb-20240814_lab.xml (EX-101.LAB) — 33KB
• renb-20240814_pre.xml (EX-101.PRE) — 22KB
• e5891_8-k_htm.xml (XML) — 4KB

02 Non-Reliance on Previously Issued

Item 4.02 Non-Reliance on Previously Issued

Financial Statements or a Related Audit Report or Completed Interim Review

Financial Statements or a Related Audit Report or Completed Interim Review. On August 14, 2024, the Audit Committee of the Board of Directors of the Company, based on the recommendation of the Company's management, and after consultation with the Company's independent registered public accounting firm, concluded that the Company's previously issued unaudited interim condensed consolidated financial statements contained within the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 contained a material misstatement related to the value of its indefinite life intangible assets (IPR&D assets), impacting the value of the IPR&D assets on the balance sheet, together with the loss on the statement of operations, and, accordingly, should no longer be relied upon. As previously disclosed in the Company's Annual Report on Form 10-K filed with the Commission on October 2, 2023, further development of the Company's product candidate RENB-HV-01 was deemed costly and a long-term undertaking and therefore it had become less attractive and had been deprioritized so that pipelines that could move more quickly could be prioritized (e.g., RENB-DC-11). On March 31, 2024, a license agreement by and between Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly-owned subsidiary of the Company, dated February 16, 2018 (the "License Agreement") covering RENB-HV-01 was terminated by the licensor. The Company's management identified an error in the March 31, 2024 financial statements resulting from the method used to measure the impairment of an indefinite life intangible asset (IPR&D asset) associated with the termination of the License Agreement. The error resulted in, among other things, an overstatement of our assets and an understatement of our net loss and net loss per share for the three and nine months ended March 31, 2024 due to an increase in the non-cash intangible asset impairment charge. Accordingly, the Company int

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 21, 2024, the Company filed suit against Weird Science LLC, William Anderson Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company and two companies closely associated with Serhat Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment, and civil conspiracy and seeks, inter alia, equitable relief, including, but not limited to, return to the Company any shares received in connection with the merger, and damages. Cautionary Note Regarding

Forward-Looking Statements

Forward-Looking Statements Certain Litigation Reform Act of 1995 and within the meaning of the federal securities laws. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties such as those set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking are available on the website of the SEC at www.sec.gov and other documents filed, or to be filed with the SEC by the Company. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ Simon Tarsh Name: Simon Tarsh Title: Interim Chief Financial Officer Date: August 19, 2024

View Full Filing

View this 8-K filing on SEC EDGAR